Sector | Healthcare | Compare with Sector peers |
Industry | Pharmaceuticals & Drugs | Compare with Industry peers |
Website | http://medicoremedies.com | |
Market Cap | 393.59 Cr. | |
Enterprise Value(EV) | 397.90 Cr. | 2023-09 |
Financial Indicators | ||
---|---|---|
Earnings per share (EPS) | 0.84 | Trailing Twelve Months Ending 2023-12 |
Price-Earning Ratio (PE) | 56.56 | Trailing Twelve Months Ending 2023-12 |
Industry PE | 41.22 | Trailing Twelve Months Ending 2023-12 |
Book Value / Share | 5.91 | Trailing Twelve Months Ending 2023-12 |
Price to Book Value | 8.02 | Calculated using Price: 47.43 |
Dividend Yield | 0.00 | Period Ending 2023-03 |
No. of Shares Subscribed | 8.30 Cr. | 82,984,000 Shares |
FaceValue | 2 | |
About Medico Remedies Ltd. | ||
The company is engaged in manufacturing and selling of pharmaceutical formulation products in India. The company offers formulation pharmacy products including anti-infective, beta lactum, cephalosporin, antimalarial, antiretroviral, and anti-ulcer drugs, as well as antacids; vitamins, haematinics and other supplements and nonsteroidal anti-inflammatory drugs, antihistaminics, anti-diabetics, cardio vascular drugs, diuretics, anti-epileptics, combination drug kits, syrups and creams and gels. |
1 Day |
|
+2.24% |
1 Week |
|
-1.14% |
1 Month |
|
-1.85% |
3 Month |
|
-47.21% |
6 Month |
|
-36.87% |
1 Year |
|
-41.14% |
2 Year |
|
|
5 Year |
|
|
10 Year |
|
9 years | 2015-03 | 2016-03 | 2017-03 | 2018-03 | 2019-03 | 2020-03 | 2021-03 | 2022-03 | 2023-03 | |
Return on Equity (%) | 7.14 | 7.97 | 10.47 | 5.67 | 5.72 | 5.61 | 8.31 | 13.94 | 18.01 | |
Return on Capital Employed (%) | 10.01 | 10.86 | 9.39 | 9.05 | 7.79 | 7.66 | 10.13 | 15.09 | 21.88 | |
Return on Assets (%) | 2.36 | 2.78 | 3.47 | 2.26 | 2.31 | 2.15 | 3.43 | 6.24 | 8.63 |
Particulars | 10 years | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. | 2023-09* Rs. Cr. |
Shh. Funds | 14 | 15 | 16 | 27 | 28 | 30 | 32 | 37 | 44 | 48 | |
Non Curr. Liab. | 1 | 4 | 11 | 3 | 3 | 5 | 5 | 3 | 2 | 2 | |
Curr. Liab. | 22 | 26 | 21 | 30 | 45 | 40 | 38 | 40 | 43 | 53 | |
Minority Int. | |||||||||||
Equity & Liab. | 36 | 46 | 48 | 59 | 76 | 75 | 76 | 79 | 89 | 102 | |
Non Curr. Assets | 10 | 9 | 10 | 14 | 17 | 19 | 17 | 20 | 23 | 22 | |
Curr. Assets | 26 | 37 | 38 | 46 | 59 | 57 | 58 | 59 | 66 | 81 | |
Misc. Exp. not W/O | |||||||||||
Total Assets | 36 | 46 | 48 | 59 | 76 | 75 | 76 | 79 | 89 | 102 |
Particulars | 10 years | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. | 2023-12 Rs. Cr. TTM |
Net Sales | 51 | 67 | 54 | 61 | 98 | 89 | 122 | 121 | 140 | 132 | |
Other Income | 0 | 0 | 0 | 1 | 2 | 2 | 1 | 2 | 4 | 2 | |
Total Income | 51 | 67 | 55 | 62 | 100 | 91 | 123 | 123 | 145 | 133 | |
Total Expenditure | -48 | -63 | -50 | -58 | -95 | -86 | -117 | -114 | -131 | -120 | |
PBIDT | 3 | 4 | 4 | 4 | 5 | 5 | 6 | 9 | 14 | 13 | |
Interest | -1 | -1 | -1 | -2 | -1 | -1 | -1 | -1 | -1 | -1 | |
Depreciation | -1 | -1 | -1 | -1 | -2 | -2 | -2 | -2 | -3 | -3 | |
Taxation | 0 | -1 | 0 | -1 | -1 | -1 | -1 | -2 | -3 | -2 | |
Exceptional Items | 0 | ||||||||||
PAT | 1 | 1 | 2 | 1 | 2 | 2 | 3 | 5 | 7 | 7 | |
Adjusted EPS | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 |
Particulars | 10 years | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. |
Cash Fr. Operatn. | 3 | 0 | -4 | -3 | 5 | 5 | 1 | -11 | 6 | 8 | |
Cash Fr. Inv. | -4 | -2 | 0 | -3 | -5 | -4 | -3 | -17 | -2 | -7 | |
Cash Fr. Finan. | 2 | 3 | 2 | 6 | -1 | -1 | 3 | 18 | -6 | -2 | |
Net Change | 1 | 0 | -1 | 0 | -1 | 0 | 0 | -10 | -2 | 0 | |
Cash & Cash Eqvt | 1 | 2 | 1 | 0 | 0 | 0 | 1 | -10 | 1 | 1 |
Mon, 22 Apr 2024
Disclosure under SEBI Takeover Regulations ᅡᅠHarshit Mehtaᅡᅠhas Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of Indiaᅡᅠ(Substantial Acquisition of Shares and Takeovers) Regulations, 2011 |
Wed, 27 Mar 2024
Trading Window Medico Remedies Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015 |
Wed, 27 Mar 2024
Trading Window-XBRL MEDICO REMEDIES LIMITED has informed the Exchange about Closure of Trading Window |
Wed, 24 Apr 2024 |
Closing Above Previous High |
Close Within 52 Week Low Zone |
High Decrease in 3 Months |
High Decrease in 6 Months |
High Decrease in 1 Year |